EUVIMEDEUVIMED entdecken
FallberichtOpen Access

Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease

Sophie Momen, Hiva Fassihi, Helen R Davies, Christos Nikolaou, Andrea Degasperi, Catherine M Stefanato, Joao M L Dias, Dhruba Dasgupta, Emma Craythorne, Robert Sarkany, Sophie Papa, Serena Nik-Zainal

Molecular Case Studies · 2019-10 · 5 (5) · a004408

DOI: 10.1101/mcs.a004408 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Molecular Case Studies, online erschienen am 23.10.2019. Verfasst von Sophie Momen und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Genetics, Addenbrooke's Treatment Centre, The Clinical School, University of Cambridge, Cambridge Biomedical Campus, Cambridge …. Die Arbeit wurde bisher 46-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Cancer Research UK, Wellcome Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

“Mutational signatures” are patterns of mutations that report DNA damage and subsequent repair processes that have occurred. Whole-genome sequencing (WGS) can provide additional information to standard diagnostic techniques and can identify therapeutic targets. A 32-yr-old male with xeroderma pigmentosum developed metastatic angiosarcoma that was unresponsive to three lines of conventional sarcoma therapies. WGS was performed on his primary cancer revealing a hypermutated tumor, including clonal ultraviolet radiation-induced mutational patterns (Signature 7) and subclonal signatures of mutated DNA polymerase epsilon ( POLE ) (Signature 10). These signatures are associated with response to immune checkpoint blockade. Immunohistochemistry confirmed high PD-L1 expression in metastatic deposits. The anti-PD-1 monoclonal antibody pembrolizumab was commenced off-label given the POLE mutation and high mutational load. After four cycles, there was a significant reduction in his disease with almost complete resolution of the metastatic deposits. This case highlights the importance of WGS in the analysis, interpretation, and treatment of cancers. We anticipate that as WGS becomes integral to the cancer diagnostic pathway, treatments will be stratified to the individual based on their unique genomic and/or transcriptomic profile, enhancing classical approaches of histologically driven treatment decisions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AdultAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenDNA Mutational AnalysisDNA Polymerase IIHemangiosarcomaHumansMaleMicrosatellite InstabilityMutationPoly-ADP-Ribose Binding ProteinsProgrammed Cell Death 1 ReceptorSkin NeoplasmsWhole Genome SequencingXeroderma Pigmentosum

Stichwörter der Autor:innen

metastatic angiosarcoma

Substanzen

Antibodies, MonoclonalAntibodies, Monoclonal, HumanizedB7-H1 AntigenCD274 protein, humanPoly-ADP-Ribose Binding ProteinsProgrammed Cell Death 1 ReceptorpembrolizumabDNA Polymerase IIPOLE protein, human

Autor:innen und Institutionen

  • Department of Medical Genetics, Addenbrooke's Treatment Centre, The Clinical School, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0QQ, United Kingdom.
  • National Xeroderma Pigmentosum Service, Department of Photodermatology, St John's Institute of Dermatology, Guy's and St Thomas' Foundation Trust, London SE1 7EH, United Kingdom.
  • MRC Cancer Unit, Hutchison/MRC Research Centre, University of Cambridge, Cambridge Biomedical Campus, Cambridge CB2 0XZ, United Kingdom.
  • Department of Medical Oncology, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, United Kingdom.
  • Department of Dermatopathology, St John's Institute of Dermatology, Guy's and St Thomas' Foundation Trust, London SE1 7EH, United Kingdom.
  • Department of Nuclear Medicine, Guy's and St Thomas' NHS Foundation Trust, Great Maze Pond, London SE1 9RT, United Kingdom.

Förderung

  • Cancer Research UK
  • Wellcome Trust

Zitieren

APA

Momen, S., Fassihi, H., Davies, H. R., Nikolaou, C., Degasperi, A., Stefanato, C. M., Dias, J. M. L., Dasgupta, D., Craythorne, E., Sarkany, R., Papa, S., & Nik-Zainal, S. (2019). Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Molecular Case Studies, 5(5), a004408. https://doi.org/10.1101/mcs.a004408

Vancouver

Momen S, Fassihi H, Davies HR, Nikolaou C, Degasperi A, Stefanato CM, et al. Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease. Molecular Case Studies. 2019;5(5):a004408. doi:10.1101/mcs.a004408

BibTeX
@article{Momen2019,
  author = {Momen, Sophie and Fassihi, Hiva and Davies, Helen R and Nikolaou, Christos and Degasperi, Andrea and Stefanato, Catherine M and Dias, Joao M L and Dasgupta, Dhruba and Craythorne, Emma and Sarkany, Robert and Papa, Sophie and Nik-Zainal, Serena},
  title = {Dramatic response of metastatic cutaneous angiosarcoma to an immune checkpoint inhibitor in a patient with xeroderma pigmentosum: whole-genome sequencing aids treatment decision in end-stage disease},
  journal = {Molecular Case Studies},
  year = {2019},
  volume = {5},
  number = {5},
  pages = {a004408},
  doi = {10.1101/mcs.a004408}
}
Kostenlos starten →